@prefix schema: <http://schema.org/> .
@prefix gndo: <https://d-nb.info/standards/elementset/gnd#> .
@prefix lib: <http://purl.org/library/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix editeur: <https://ns.editeur.org/thema/> .
@prefix geo: <http://www.opengis.net/ont/geosparql#> .
@prefix umbel: <http://umbel.org/umbel#> .
@prefix naf: <https://id.loc.gov/authorities/names/> .
@prefix sf: <http://www.opengis.net/ont/sf#> .
@prefix rdau: <http://rdaregistry.info/Elements/u/> .
@prefix bflc: <http://id.loc.gov/ontologies/bflc/> .
@prefix thesoz: <http://lod.gesis.org/thesoz/> .
@prefix dcterms: <http://purl.org/dc/terms/> .
@prefix isbd: <http://iflastandards.info/ns/isbd/elements/> .
@prefix foaf: <http://xmlns.com/foaf/0.1/> .
@prefix mesh: <http://id.nlm.nih.gov/mesh/vocab#> .
@prefix ram: <https://data.bnf.fr/ark:/12148/> .
@prefix mo: <http://purl.org/ontology/mo/> .
@prefix marcRole: <http://id.loc.gov/vocabulary/relators/> .
@prefix agrelon: <https://d-nb.info/standards/elementset/agrelon#> .
@prefix dcmitype: <http://purl.org/dc/dcmitype/> .
@prefix nsogg: <https://purl.org/bncf/tid/> .
@prefix dnbt: <https://d-nb.info/standards/elementset/dnb#> .
@prefix dbp: <http://dbpedia.org/property/> .
@prefix embne: <https://datos.bne.es/resource/> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix dnb_intern: <http://dnb.de/> .
@prefix madsrdf: <http://www.loc.gov/mads/rdf/v1#> .
@prefix v: <http://www.w3.org/2006/vcard/ns#> .
@prefix cidoc: <http://www.cidoc-crm.org/cidoc-crm/> .
@prefix dcatde: <http://dcat-ap.de/def/dcatde/> .
@prefix ebu: <http://www.ebu.ch/metadata/ontologies/ebucore/ebucore#> .
@prefix wdrs: <http://www.w3.org/2007/05/powder-s#> .
@prefix bibo: <http://purl.org/ontology/bibo/> .
@prefix gbv: <http://purl.org/ontology/gbv/> .
@prefix agrovoc: <https://aims.fao.org/aos/agrovoc/> .
@prefix lcsh: <https://id.loc.gov/authorities/subjects/> .
@prefix dc: <http://purl.org/dc/elements/1.1/> .

<https://d-nb.info/1328807193> a bibo:Issue;
  dcterms:medium <http://rdaregistry.info/termList/RDACarrierType/1018>;
  rdau:P60049 <http://rdaregistry.info/termList/RDAContentType/1020>;
  rdau:P60050 <http://rdaregistry.info/termList/RDAMediaType/1003>;
  rdau:P60048 <http://rdaregistry.info/termList/RDACarrierType/1018>;
  dc:identifier "(DE-101)1328807193";
  umbel:isLike <https://doi.org/10.1055/a-2266-7984>, <https://nbn-resolving.org/urn:nbn:de:101:1-2405091126387.326018610201>;
  dc:identifier "(OCoLC)1562564743";
  dcterms:language <http://id.loc.gov/vocabulary/iso639-2/eng>;
  a bibo:Article;
  dc:title "Use of Vonicog Alpha and Acquired von Willebrand Syndrome, a New Approach: A Case Report";
  marcRole:oth _:node1k0rml8akx37535113 .

_:node1k0rml8akx37535113 gndo:preferredName "Blandinières, Adeline" .

<https://d-nb.info/1328807193> marcRole:oth _:node1k0rml8akx37535114 .

_:node1k0rml8akx37535114 gndo:preferredName "Combe, Sophie" .

<https://d-nb.info/1328807193> marcRole:oth <https://d-nb.info/gnd/1380794676>, _:node1k0rml8akx37535115 .

_:node1k0rml8akx37535115 gndo:preferredName "Lambotte, Olivier" .

<https://d-nb.info/1328807193> marcRole:oth _:node1k0rml8akx37535116 .

_:node1k0rml8akx37535116 gndo:preferredName "Lavenu-Bombled, Cécile" .

<https://d-nb.info/1328807193> dcterms:isPartOf <https://ld.zdb-services.de/resource/2030152-2>;
  dcterms:description "Abstract: Therapeutic management of acquired von Willebrand syndrome (AVWS) can be challenging, particularly in cases of AVWS associated with monoclonal IgM such as Waldenström macroglobulinemia (WM) where several therapeutic options may be ineffective. Here, we describe the case of an 88-year-old patient who developed AVWS during follow-up for WM. The presence of a severe bleeding symptomatology not controlled by several therapies (plasma-derived von Willebrand factor, plasmapheresis) led us to introduce a supplementation with recombinant von Willebrand factor, vonicog α (Veyvondi, Takeda, Japan), starting at a dose of 50 IU/kg/d. This supplementation allowed clinical (no further bleeding) and biological (hemoglobin level, von Willebrand factor parameters) improvements. Because of the persistence of bleeding risk factors, the treatment was maintained at a prophylactic dose (20 UI/kg three times a week), without recurrence of bleeding events for a period of 9 months."@de;
  wdrs:describedby <https://d-nb.info/1328807193/about> .

<https://d-nb.info/1328807193/about> dcterms:license <http://creativecommons.org/publicdomain/zero/1.0/>;
  dcterms:modified "2026-02-15T17:04:04.000"^^xsd:dateTime .

<https://d-nb.info/1328807193> dcterms:issued "2024";
  bibo:issue "2024-03-22";
  owl:sameAs <http://hub.culturegraph.org/resource/DNB-1328807193> .